Atlas Trials

Wuhan YZY Biopharma Co., Ltd.

8 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Wuhan YZY Biopharma Co., Ltd.

RecordFirmDate
Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody (NCT06432296)Wuhan YZY Biopharma Co., Ltd.2024-03-25
A Trial of Y101D in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Advanced Pancreatic Cancer (NCT06266143)Wuhan YZY Biopharma Co., Ltd.2023-02-08
A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC (NCT05543330)Wuhan YZY Biopharma Co., Ltd.2022-09-30
A Trial of Y101D, a PD-L1/TGF-β Bispecific Antibody, in Patients With Metastatic or Locally Advanced Solid Tumors (NCT05028556)Wuhan YZY Biopharma Co., Ltd.2021-08-06
A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma (NCT05011097)Wuhan YZY Biopharma Co., Ltd.2021-07-08
A Study of M701 (EpCAM and CD3) in Malignant Ascites (NCT04501744)Wuhan YZY Biopharma Co., Ltd.2018-09-30
A Study of M802 (HER2 and CD3) in HER2-Positive Advanced Solid Tumors (NCT04501770)Wuhan YZY Biopharma Co., Ltd.2018-09-27

Track Wuhan YZY Biopharma Co., Ltd. automatically

Every clearance here is in the API, with alerts when new ones post.